LVW Advisors’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $5.02M | Buy |
19,932
+399
| +2% | +$85.8K | 0.43% | 38 |
|
|
2026
Q1 | $4.25M | Buy |
19,533
+1,955
| +11% | +$434K | 0.4% | 35 |
|
|
2025
Q4 | $4.02M | Sell |
17,578
-365
| -2% | -$83.1K | 0.41% | 34 |
|
|
2025
Q3 | $4.15M | Sell |
17,943
-911
| -5% | -$186K | 0.42% | 35 |
|
|
2025
Q2 | $3.5M | Sell |
18,854
-2,690
| -12% | -$500K | 0.38% | 36 |
|
|
2025
Q1 | $4.51M | Sell |
21,544
-479
| -2% | -$93.1K | 0.54% | 28 |
|
|
2024
Q4 | $3.91M | Sell |
22,023
-1,229
| -5% | -$226K | 0.47% | 34 |
|
|
2024
Q3 | $4.59M | Sell |
23,252
-908
| -4% | -$169K | 0.58% | 31 |
|
|
2024
Q2 | $4.14M | Sell |
24,160
-687
| -3% | -$114K | 0.61% | 29 |
|
|
2024
Q1 | $4.52M | Sell |
24,847
-1,897
| -7% | -$327K | 0.77% | 24 |
|
|
2023
Q4 | $4.14M | Sell |
26,744
-2,859
| -10% | -$417K | 0.78% | 26 |
|
|
2023
Q3 | $4.41M | Sell |
29,603
-3,590
| -11% | -$527K | 0.91% | 23 |
|
|
2023
Q2 | $4.47M | Sell |
33,193
-2,421
| -7% | -$355K | 0.86% | 24 |
|
|
2023
Q1 | $5.68M | Sell |
35,614
-1,851
| -5% | -$283K | 1.11% | 16 |
|
|
2022
Q4 | $6.05M | Sell |
37,465
-1,506
| -4% | -$231K | 1.23% | 13 |
|
|
2022
Q3 | $5.23M | Buy |
38,971
+26
| +0.1% | +$3.73K | 1.17% | 16 |
|
|
2022
Q2 | $5.96M | Sell |
38,945
-4,855
| -11% | -$742K | 1.21% | 14 |
|
|
2022
Q1 | $7.1M | Sell |
43,800
-1,561
| -3% | -$227K | 1.2% | 14 |
|
|
2021
Q4 | $6.14M | Sell |
45,361
-4,106
| -8% | -$485K | 1.05% | 14 |
|
|
2021
Q3 | $5.34M | Buy |
49,467
+414
| +0.8% | +$47.3K | 0.92% | 23 |
|
|
2021
Q2 | $5.53M | Buy |
49,053
+584
| +1% | +$65.8K | 0.98% | 22 |
|
|
2021
Q1 | $5.25M | Sell |
48,469
-605
| -1% | -$64.7K | 1.01% | 21 |
|
|
2020
Q4 | $5.26M | Sell |
49,074
-44
| -0.1% | -$4.23K | 1.05% | 20 |
|
|
2020
Q3 | $4.3M | Sell |
49,118
-2,478
| -5% | -$233K | 0.95% | 22 |
|
|
2020
Q2 | $5.07M | Sell |
51,596
-9
| -0% | -$792 | 1.22% | 16 |
|
|
2020
Q1 | $3.93M | Buy |
51,605
+1,250
| +2% | +$106K | 1.05% | 20 |
|
|
2019
Q4 | $4.46M | Sell |
50,355
-368
| -0.7% | -$30.6K | 1.01% | 22 |
|
|
2019
Q3 | $3.84M | Buy |
50,723
+11,712
| +30% | +$803K | 0.95% | 24 |
|
|
2019
Q2 | $2.84M | Buy |
39,011
+4,817
| +14% | +$379K | 0.78% | 36 |
|
|
2019
Q1 | $2.76M | Sell |
34,194
-498
| -1% | -$40.7K | 0.73% | 39 |
|
|
2018
Q4 | $3.2M | Buy |
34,692
+3,679
| +12% | +$324K | 1.08% | 25 |
|
|
2018
Q3 | $2.93M | Buy |
31,013
+532
| +2% | +$50.5K | 0.82% | 28 |
|
|
2018
Q2 | $2.82M | Buy |
30,481
+157
| +0.5% | +$15.3K | 0.9% | 26 |
|
|
2018
Q1 | $2.87M | Sell |
30,324
-4,219
| -12% | -$463K | 0.89% | 25 |
|
|
2017
Q4 | $3.34M | Sell |
34,543
-3,342
| -9% | -$315K | 0.98% | 27 |
|
|
2017
Q3 | $3.37M | Sell |
37,885
-1,383
| -4% | -$105K | 1.34% | 18 |
|
|
2017
Q2 | $2.85M | Sell |
39,268
-1,283
| -3% | -$86.3K | 1% | 21 |
|
|
2017
Q1 | $2.64M | Sell |
40,551
-2,128
| -5% | -$134K | 0.95% | 31 |
|
|
2016
Q4 | $2.67M | Buy |
42,679
+846
| +2% | +$51.6K | 0.93% | 30 |
|
|
2016
Q3 | $2.64M | Buy |
41,833
+743
| +2% | +$48.1K | 0.86% | 30 |
|
|
2016
Q2 | $2.54M | Sell |
41,090
-549
| -1% | -$33.5K | 0.96% | 28 |
|
|
2016
Q1 | $2.38M | Buy |
41,639
+2,187
| +6% | +$122K | 0.76% | 32 |
|
|
2015
Q4 | $2.34M | Buy |
39,452
+83
| +0.2% | +$4.78K | 0.92% | 29 |
|
|
2015
Q3 | $2.14M | Sell |
39,369
-1,371
| -3% | -$89.2K | 0.99% | 31 |
|
|
2015
Q2 | $2.74M | Buy |
40,740
+390
| +1% | +$25.5K | 1.16% | 22 |
|
|
2015
Q1 | $2.36M | Buy |
40,350
+1,862
| +5% | +$112K | 1.12% | 26 |
|
|
2014
Q4 | $2.52M | Buy |
+38,488
| New | +$2.43M | 1.39% | 24 |
|
Other funds holding ABBV
ECSS
ATO
LVW Advisors's ABBV Position: Q2 2026 in Review
LVW Advisors increased its AbbVie (ABBV) stake by 2% in Q2 2026, buying an estimated $85.8K and bringing the position to 19,932 shares worth $5.02M. The position accounts for 0.43% of the portfolio, ranked #38.
LVW Advisors first reported a position in ABBV in Q4 2014 and has held it in 47 quarters since. The position peaked at $7.1M in Q1 2022. 2,121 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- LVW Advisors held 19,932 shares of AbbVie worth $5.02M as of Q2 2026.
- LVW Advisors bought 399 AbbVie shares in Q2 2026, an estimated $85.8K.
- AbbVie made up 0.43% of LVW Advisors's portfolio in Q2 2026, its #38 holding.
- LVW Advisors first reported a position in AbbVie in Q4 2014 and has held it in 47 quarters since.
- LVW Advisors's AbbVie position peaked at $7.1M in Q1 2022.
- 2,121 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on LVW Advisors's 13F filing for Q2 2026, filed 15 Jul 2026.